Literature DB >> 17356133

Activation mechanisms of STAT5 by oncogenic Flt3-ITD.

Chunaram Choudhary1, Christian Brandts, Joachim Schwable, Lara Tickenbrock, Bülent Sargin, Andrea Ueker, Frank-D Böhmer, Wolfgang E Berdel, Carsten Müller-Tidow, Hubert Serve.   

Abstract

Mutations in the receptor tyrosine kinase Flt3 represent a very common genetic lesion in acute myeloid leukemia (AML). Internal tandem duplication (ITD) mutations clustered in the juxtamembrane domain are the most frequent and best characterized mutations found in Flt3. Oncogenic activation of Flt3 by ITD mutations is known to activate aberrant signaling including activation of STAT5 and repression of myeloid transcription factors Pu.1 and c/EBP-alpha. However, the mechanisms of STAT5 activation by Flt3-ITD remain unclear. Using small molecule inhibitors and cell lines deficient for Src family kinases or Jak2 or Tyk2, here we show that Flt3-ITD-induced STAT5 activation is independent of Src or Jak kinases. Also, overexpression of SOCS1, an inhibitor of Jak kinases, inhibited IL-3- but not Flt3-ITD-mediated STAT5 activation. Furthermore, in vitro kinase assays revealed that STAT5 is a direct target of Flt3. Taken together, our data provide the mechanistic basis of STAT5 activation by Flt3-ITD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17356133     DOI: 10.1182/blood-2006-05-024018

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  94 in total

1.  Activation of Wnt signaling in cKit-ITD mediated transformation and imatinib sensitivity in acute myeloid leukemia.

Authors:  Lara Tickenbrock; Sina Hehn; Bülent Sargin; Georg Evers; Pavankumar Reddy Ng; Chunaram Choudhary; Wolfgang E Berdel; Carsten Müller-Tidow; Hubert Serve
Journal:  Int J Hematol       Date:  2008-07-31       Impact factor: 2.490

Review 2.  Dendritic cell homeostasis.

Authors:  Miriam Merad; Markus G Manz
Journal:  Blood       Date:  2009-01-27       Impact factor: 22.113

Review 3.  A STATus report on DC development.

Authors:  Haiyan S Li; Stephanie S Watowich
Journal:  J Leukoc Biol       Date:  2012-05-01       Impact factor: 4.962

4.  The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.

Authors:  Ewa Augustin; Anna Skwarska; Anna Weryszko; Iwona Pelikant; Ewa Sankowska; Barbara Borowa-Mazgaj
Journal:  Acta Pharmacol Sin       Date:  2015-02-02       Impact factor: 6.150

Review 5.  Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.

Authors:  Tariq I Mughal; Saulius Girnius; Steven T Rosen; Shaji Kumar; Adrian Wiestner; Omar Abdel-Wahab; Jean-Jacques Kiladjian; Wyndham H Wilson; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2014-02-17

6.  A robust error model for iTRAQ quantification reveals divergent signaling between oncogenic FLT3 mutants in acute myeloid leukemia.

Authors:  Yi Zhang; Manor Askenazi; Jingrui Jiang; C John Luckey; James D Griffin; Jarrod A Marto
Journal:  Mol Cell Proteomics       Date:  2009-12-17       Impact factor: 5.911

Review 7.  Targeting signal transducer and activator of transcription signaling pathway in leukemias.

Authors:  Mustafa Benekli; Heinz Baumann; Meir Wetzler
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

8.  Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment.

Authors:  Linhua Jin; Yoko Tabe; Hongbo Lu; Gautam Borthakur; Takashi Miida; Hagop Kantarjian; Michael Andreeff; Marina Konopleva
Journal:  Cancer Lett       Date:  2012-10-02       Impact factor: 8.679

9.  MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.

Authors:  Suiyang Liu; Li Yin; Dina Stroopinsky; Hasan Rajabi; Alexandre Puissant; Kimberly Stegmaier; David Avigan; Surender Kharbanda; Donald Kufe; Richard Stone
Journal:  Blood       Date:  2013-11-26       Impact factor: 22.113

10.  NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.

Authors:  D Gerloff; R Grundler; A A Wurm; D Bräuer-Hartmann; C Katzerke; J-U Hartmann; V Madan; C Müller-Tidow; J Duyster; D G Tenen; D Niederwieser; G Behre
Journal:  Leukemia       Date:  2014-08-05       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.